Scholar Rock Holding Corporation (SRRK )

Currency in USD Disclaimer
$36.03 -$1.38 (-3.69%)
Open 11/17/2025
$35.85
$37.07
$22.71
$46.98

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol SRRK
  • Company Scholar Rock Holding Corporation
  • Price $36.03
  • Changes Percentage -3.69
  • Change -1.38
  • Day Low $35.85
  • Day High $37.07
  • Year High $46.98
  • Year Low $22.71
  • Market Cap $3,476,923,175
  • Price Avg 50 EMA (D) $32.45
  • Price Avg 200 EMA (D) $33.65
  • Exchange NASDAQ
  • Volume 1,491,906
  • Average Volume 2,600,240
  • Open $36.92
  • Previous Close $37.41
  • EPS -2.92
  • PE -12.39
  • Earnings Announcement 2025-11-14 13:30:00
  • Shares Outstanding $96,127,265

Company brief: SCHOLAR ROCK HOLDING CORPORATION (SRRK )

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

SRRK Corporation News

Income Statement